$TWST

CHESS ROBERT sold $2.0M of TWST

CHESS ROBERT sold 18,417 shares of Twist Bioscience Corp (TWST) at $110.89 ($2.04M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CHESS ROBERT
Published Aug 11, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director, executed under a pre-arranged Rule 10b5-1 plan, with no accompanying corporate or operational news.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 framing and lack of fundamental updates make it unlikely to drive a durable repricing.

03

What to watch

The article does not state whether the director’s remaining holdings are large relative to prior sales, nor does it provide context on total insider activity around the same period.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-11, covering a sale dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

SEC Form 4 shows director CHESS ROBERT sold 18,417 shares of Twist Bioscience at $110.89 on 2026-08-07 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only rather than a fundamental change.

Evidence & confidence

The filing is a routine Form 4 transaction with stated 10b5-1 pre-arrangement, and it does not include new company fundamentals (guidance, contracts, trials, or regulatory actions).

Market effects

No direct sector read-through; this is company-specific insider selling without accompanying operational updates.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can still be interpreted by some traders as confidence-neutral to cautious, especially if paired with other negative signals not present here.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • CHESS ROBERT

    Director who sold 18,417 shares on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.